Status:
COMPLETED
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Lead Sponsor:
Sanofi
Conditions:
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occ...
Detailed Description
The maximal duration of the study participation for patients was 41 weeks and one day, split in: * a 2-week screening period, * a 39-week treatment period: 3 treatment periods of 13 weeks with a cros...
Eligibility Criteria
Inclusion
- Type 1 diabetic subjects
- Treated with insulin for at least 2 years and by CSII for at least 6 months
- Using the same insulin (insulin glulisine, insulin aspart or insulin lispro) in CSII for at least 3 months with the same external pump compatible with the 3 short acting insulin analogues used in the study
- Using the same type of infusion set (catheter and cannula) for at least 3 months
- Performing at least 3 blood glucose controls per day
- HbA1c \< 8.5%
- Body mass index (BMI) \< 35 kg/m²
- Ability and willingness to perform blood glucose and ketone monitoring using the Sponsor-provided combined glucose and ketone meter and patient diary at home
Exclusion
- Diabetes other than Type 1
- Total daily dose of insulin greater than 90 U/day
- Using an insulin pump requiring pre-filled cartridges
- History of infection at infusion site requiring a drainage in the last 3 months
- History of severe episodes of ketosis requiring hospitalization in the last 6 months
- Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study. An ophthalmoscopic examination should have been performed in the 2 years prior to study entry
- Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method) or breastfeeding
- Treatment with systemic corticosteroids or medication known to influence insulin sensitivity in the 3 months prior to visit 1
- Treatment with antidiabetic drug other than insulin in the 3 months prior to visit 1
- Likelihood of requiring treatments during the study which are not permitted
- Treatment with an investigational product in the 30 days prior to visit 1
- History of sensitivity to the study drugs or to drugs with a similar chemical structure
- Presence of any condition (medical, including clinically significant abnormal laboratory test, psychological, social or geographical) actual or anticipated that the Investigator feels would compromise the patient safety or limit his/her successful participation in the study
- Night shift workers
- Impaired renal function as shown by serum creatinine ≥1.5 mg/dL (133 μmol/L) or ≥1.4 mg/dL (124 μmol/L) in men and women, respectively
- Impaired hepatic function as shown by Alanine aminotransferase (ALT) and/or Aspart aminotransferase (AST) greater than three times the upper limit of normal range)
- Alcohol or drug abuse in the last year
- Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
289 Patients enrolled
Trial Details
Trial ID
NCT00607087
Start Date
January 1 2008
End Date
June 1 2009
Last Update
August 31 2010
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States
2
Sanofi-Aventis Administrative Office
Macquarie Park, Australia
3
Sanofi-Aventis Administrative Office
Vienna, Austria
4
Sanofi-Aventis Administrative Office
Paris, France